Landscape of Gout in French Polynesia. (METABOGOUT)

Lille Catholic University

Status: Enrolling

Conditions: Metabolic Diseases; Inflammation; Gout Disease

Treatments: Other: Epidemiological study; Diagnostic Test: Blood and urine tests

Study type: Observational

Funder types: Other

Identifiers

NCT07343336

RC-P00126

Details and patient eligibility

About

The aim of this research is to characterise the genetic and molecular landscape of gout, inflammation and metabolic diseases, as well as the associated molecular, anthropomorphic and pathological characteristics.

Full description

Recent work by the GHICL has highlighted the imminent public health problem represented by gout and hyperuricaemia in French Polynesia, with gout affecting around 15% and hyperuricaemia 71.6% of the adult population.

Hyperuricaemia is defined as a serum urate level above the saturation point, leading to its crystallisation under biological conditions. It is generally accepted that hyperuricaemia (HU) begins at 6.0 mg/dL (360 µmol/L).

The best-known consequence of hyperuricaemia is the development of gout, which results from the inflammatory response to the presence of monosodium urate (MSU) crystals in and around the joints. The factors modulating the deposition of MSU crystals in HU are poorly understood and a potential genetic contribution is unknown. It is known that the inflammatory response to the presence of MSU crystal deposits causing gout flares is mediated by activation of the NLRP33 inflammasome, but there is significant variability in this inflammatory response within the same individual (irregular recurrence of flares), and between individuals. The exceptionally high prevalence of HU that have been identified in French Polynesia represents a major health burden, as hyperuricaemia and gout are associated with many other cardiometabolic diseases.

For example, hyperuricaemia, BMI and type 2 diabetes are all associated with the risk of gout. The association between gout and cardiovascular events is also well known, and is thought to be mediated by a persistent inflammatory state. These data are particularly relevant in the context of French Polynesia where, in addition to high rates of gout and HU, a prevalence of obesity of over 40% (BMI >30kg/m2) and a prevalence of diabetes (based on HBA1c measurements) of over 13% was previously identified by the same team.

This last point is particularly striking as the prevalence of diabetes based on self-reported diagnosis was only 7%, indicating that many people are probably undiagnosed and therefore untreated. A better understanding not only of the mechanism and causal link between these conditions and risk factors, but also of the genetic basis of the disease, could lead to the development of therapies and to the improvement in diagnosis. This is particularly crucial in French Polynesia, where hyperuricaemia and its pathological effects on cardiometabolic health affect a large proportion of the adult population.

Here a multi-pronged approach to take advantage of a previous study named 'TOPATA' (NCT04812886) performed previously in French Polynesia, is proposed. The idea is to expand the existing cohort, in order to identify the genetic effectors contributing to the high rates of metabolic diseases previously observed, and to track the longitudinal impacts of HU.

Enrollment: 2,750 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

All participants:

• Age between 18 and 75 years old inclusive
• Signature of informed consent
• Fasting for the collection of biological samples
• Declared Polynesian ancestry
• Affiliated to a social security scheme

General population group :

• Not having participated to the 2021 TOPATA study
• Visiting a general practitioner (for whatever reason)

Gout Group :

• Managed at the rheumatology clinic of the Taaone Hospital Centre (CHT) in Papeete by Dr Baptiste Gérard.

Tophaceous gout sub-group:

• Present with tophaceous gout.

Gout crisis subgroup:

• Be within 48 hours of the onset of a gout attack

• Agree to return 1 week after inclusion for the second blood and urine sample.

  2021 follow-up group:

• To have been included in the TOPATA study in 2021

• Have taken the genetic and biological samples that generated the genetic and serum urate data for the 2021 study

• Have hyperuricaemia without signs of gout OR without hyperuricaemia or gout at the time of inclusion in TOPATA

Exclusion criteria

All participants :

• Refusal or inability to understand or give consent

• Physical inability to follow and respect the protocol

• 1st degree relative*,

• Person under guardianship or trusteeship

• Pregnant or breast-feeding woman

  * If several relatives from the same household are eligible to participate, only one person may be included in the study. The choice is left to the discretion of the investigator or the first person met. However, both members of a couple (e.g. husband and wife) may participate.

• General population group :

• Unable to return for sampling if required.

• Gout group :

• Person wearing a knee prosthesis

• People suffering from other inflammatory rheumatic diseases

Trial design

2,750 participants in 3 patient groups

General Population Group

Description:

Patients aged between 18 and 75 years old who did not take part in the TOPATA study in 2021 and who visit their general practitioner for a consultation (for whatever reason)

Treatment:

Diagnostic Test: Blood and urine tests

Other: Epidemiological study

Gout Group

Description:

Patients aged between 18 and 75 years old who are treated at the rheumatology clinic of the Taaone Hospital Centre (CHT) in Papeete by Dr Baptiste Gérard. * There is a tophaceous gout subgroup: patients with tophaceous gout. * And a gout attack subgroup: patients presenting with a gout crisis.

Treatment:

Diagnostic Test: Blood and urine tests

Other: Epidemiological study

Follow-up group 2021

Description:

Patients aged between 18 and 75 years old who were included in the TOPATA study in 2021 and for whom genetic and biological samples during the 2021 study were taken. Patients must have had hyperuricaemia without signs of gout OR without hyperuricaemia or gout at the time of inclusion in the 2021 TOPATA study.

Treatment:

Diagnostic Test: Blood and urine tests

Other: Epidemiological study